Cargando…
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs—disulfiram and ritonavir
Based on reporting in the last several years, an impressive but dismal list of cytotoxic chemotherapies that fail to prolong the median overall survival of patients with glioblastoma has prompted the development of treatment protocols designed to interfere with growth-facilitating signaling systems...
Autor principal: | Kast, Richard E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593370/ https://www.ncbi.nlm.nih.gov/pubmed/25963312 http://dx.doi.org/10.1186/s40880-015-0010-1 |
Ejemplares similares
-
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014) -
Oxidizing to death: Disulfiram for cancer cell killing
por: Brüning, Ansgar, et al.
Publicado: (2014) -
Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide
por: Triscott, Joanna, et al.
Publicado: (2012) -
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021) -
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
por: Liu, Chan-Chuan, et al.
Publicado: (2021)